[go: up one dir, main page]

WO2025062016A3 - Biomarqueurs pour le traitement par inhibiteur de tlr - Google Patents

Biomarqueurs pour le traitement par inhibiteur de tlr Download PDF

Info

Publication number
WO2025062016A3
WO2025062016A3 PCT/EP2024/076541 EP2024076541W WO2025062016A3 WO 2025062016 A3 WO2025062016 A3 WO 2025062016A3 EP 2024076541 W EP2024076541 W EP 2024076541W WO 2025062016 A3 WO2025062016 A3 WO 2025062016A3
Authority
WO
WIPO (PCT)
Prior art keywords
biomarkers
tlr inhibitor
inhibitor treatment
treatment
tlr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/076541
Other languages
English (en)
Other versions
WO2025062016A2 (fr
Inventor
Andrew Bender
Yin Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2023/081191 external-priority patent/WO2024100139A1/fr
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of WO2025062016A2 publication Critical patent/WO2025062016A2/fr
Publication of WO2025062016A3 publication Critical patent/WO2025062016A3/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rehabilitation Therapy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne divers biomarqueurs pour identifier des patients qui sont susceptibles de répondre positivement à un traitement avec un inhibiteur de TLR.
PCT/EP2024/076541 2023-09-22 2024-09-20 Biomarqueurs pour le traitement par inhibiteur de tlr Pending WO2025062016A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202363584630P 2023-09-22 2023-09-22
US63/584,630 2023-09-22
US202363591300P 2023-10-18 2023-10-18
US63/591,300 2023-10-18
PCT/EP2023/081191 WO2024100139A1 (fr) 2022-11-09 2023-11-08 Utilisation de l'activité ifn-i en tant que biomarqueur dans le traitement d'un inhibiteur de tlr
EPPCT/EP2023/081191 2023-11-08

Publications (2)

Publication Number Publication Date
WO2025062016A2 WO2025062016A2 (fr) 2025-03-27
WO2025062016A3 true WO2025062016A3 (fr) 2025-05-01

Family

ID=92816478

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/076541 Pending WO2025062016A2 (fr) 2023-09-22 2024-09-20 Biomarqueurs pour le traitement par inhibiteur de tlr

Country Status (1)

Country Link
WO (1) WO2025062016A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007123976A2 (fr) * 2006-04-18 2007-11-01 The Board Of Trustees Of The Leland Stanford Junior University Établissement de profils d'anticorps pour la détermination de la sensibilité des patients à un traitement
WO2008137835A2 (fr) * 2007-05-03 2008-11-13 Medimmune, Llc Marqueurs d'auto-anticorps de maladie auto-immune

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007123976A2 (fr) * 2006-04-18 2007-11-01 The Board Of Trustees Of The Leland Stanford Junior University Établissement de profils d'anticorps pour la détermination de la sensibilité des patients à un traitement
WO2008137835A2 (fr) * 2007-05-03 2008-11-13 Medimmune, Llc Marqueurs d'auto-anticorps de maladie auto-immune

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOUTET M.A. ET AL.: "Interleukin-36 family dysregulation drives joint inflammation and therapy response in psoriatic arthritis", RHEUMATOLOGY, vol. 59, 3 September 2019 (2019-09-03), pages 828 - 838, XP093235830 *
DE CEUNINCK F. ET AL.: "IFN-alpha: A key therapeutic target for multiple autoimmune rheumatic diseases", DRUG DISCOV. TODAY, vol. 26, no. 10, 3 July 2021 (2021-07-03), pages 2465 - 2473, XP086832027 *
KLOPP-SCHULZE L. ET AL.: "Applying modeling and simulations for rational dose selection of novel toll-like receptor 7/8 inhibitor enpatoran for indications of high medical need", CLIN. PHARMACOL. THER., vol. 112, no. 2, August 2022 (2022-08-01), pages 297 - 306, XP093235863 *
PORT A. ET AL: "Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8", PHARMACOL. RES. PERSPECT., vol. 9, E00842, 2021, pages 1 - 12, XP093235874 *
VLACH J. ET AL.: "Discovery of M5049: A novel selective Toll-Like receptor 7/8 inhibitor for the treatment of autoimmunity", J. PHARMACOL. EXP. THERAP., vol. 376, no. 3, 19 February 2021 (2021-02-19), pages 397 - 409, XP055831586 *

Also Published As

Publication number Publication date
WO2025062016A2 (fr) 2025-03-27

Similar Documents

Publication Publication Date Title
CL2021002880S1 (es) Estuche de auriculares. (divisional solicitud 202000595)
BR112022012890A2 (pt) Instrumento cirúrgico que compreende um circuito flexível
MX2023013912A (es) Metodos para inhibir ras.
MY209340A (en) Egfr inhibitor for the treatment of cancer
MX2016001854A (es) Composiciones y metodo para tratar condiciones asociadas con el complemento.
EP4286005A3 (fr) Traitement du cancer
WO2020191041A3 (fr) Biomarqueurs pour le vitiligo
WO2021002986A3 (fr) Inhibiteurs de bax et leurs utilisations
WO2021145798A3 (fr) Procédés d'évaluation d'âge biologique et systèmes utilisant de tels procédés
EA202190475A1 (ru) Мини-gde для лечения гликогеноза iii типа
PH12020551080A1 (en) Combination therapy for treating or preventing cancer
WO2020209988A3 (fr) Panel de marqueurs divers pour le diagnostic et le traitement du tdp
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
MX2021008865A (es) Inhibidores de magl para usarse para tratar enfermedades antecedentes.
WO2020033019A3 (fr) Nouveaux inhibiteurs de mct4 et leurs utilisations
PH12021551949A1 (en) Cancer treatment
MX2021014251A (es) Compuestos de oxatiazina para la inhibicion de gliceraldehido-3-fosfato deshidrogenasa (gapdh).
WO2025062016A3 (fr) Biomarqueurs pour le traitement par inhibiteur de tlr
MX2020007664A (es) Terapia de combinacion para tratar o prevenir el cancer.
CA227224S (en) Inhaler
WO2021102359A3 (fr) Inhibiteurs de taspase1 et leurs utilisations
MX2024012789A (es) Inhibidores de fosfoinositida 3-cinasa alfa (pi3kalfa)
EP3956793A4 (fr) Moteur de modification de source
WO2019141999A8 (fr) Polytherapie pour le traitement ou la prévention du cancer
MX2020007681A (es) Terapia de combinacion para tratar o prevenir el cancer.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24773091

Country of ref document: EP

Kind code of ref document: A2